Showing results (21-30 of 382) with videos related to
Sort By:
Pageof 39
Future Oncology (London, England)|March 25, 2006
Current developments in adenovirus-based cancer gene therapyDaniel T Rein, M Breidenbach, David T CurielACS Synthetic Biology|January 10, 2023
Synthetic Biology Design as a Paradigm Shift toward Manufacturing Affordable Adeno-Associated Virus Gene TherapiesLogan Thrasher Collins, Selvarangan Ponnazhagan, David T CurielCurrent Opinion in Gastroenterology|April 30, 2025
Gut-directed therapeutics in inflammatory bowel diseaseChristina Kratschmer, David T Curiel, Matthew A CiorbaNature Reviews. Genetics|July 4, 2007
Engineering targeted viral vectors for gene therapyReinhard Waehler, Stephen J Russell, David T CurielMolecular Biotechnology|October 31, 2002
Genetically engineered intracellular single-chain antibodies in gene therapyGuadalupe Bilbao, Juan Luis Contreras, David T CurielJournal of Virology|June 20, 2002
Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IXIgor P Dmitriev, Elena A Kashentseva, David T CurielJournal of Inherited Metabolic Disease|June 30, 2021
Mucopolysaccharidoses type I gene therapySarah C Hurt, Patricia I Dickson, David T CurielClinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenovirusesKaori Suzuki, Ramón Alemany, Masato Yamamoto, et al.Hematology/Oncology Clinics of North America|September 10, 2003
Gene therapy for ovarian cancer: progress and potentialTyler O Kirby, David T Curiel, Ronald D AlvarezInternational Journal of Molecular Medicine|September 12, 2006
A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapyTanja Hakkarainen, Akseli Hemminki, David T Curiel, et al.Pageof 39